Zhou Dahui, Zhou Ping, Evrard Deborah A, Meagher Kristin, Webb Michael, Harrison Boyd L, Huryn Donna M, Golembieski Jeannette, Hornby Geoffrey A, Schechter Lee E, Smith Deborah L, Andree Terrance H, Mewshaw Richard E
Chemical and Screening Sciences, Wyeth Research, CN 8000, Princeton, NJ 08543-8000, USA.
Bioorg Med Chem. 2008 Jul 15;16(14):6707-23. doi: 10.1016/j.bmc.2008.05.075. Epub 2008 Jun 5.
Based on the previously reported discovery lead, 3-(cis-4-(4-(1H-indol-4-yl)piperazin-1-yl)cyclohexyl)-5-fluoro-1H-indole (2), a series of related arylpiperazin-4-yl-cyclohexyl indole analogs were synthesized then evaluated as 5-HT transporter inhibitors and 5-HT(1A) receptor antagonists. The investigation of the structure-activity relationships revealed the optimal pharmacophoric elements required for activities in this series. The best example from this study, 5-(piperazin-1-yl)quinoline analog (trans-20), exhibited equal binding affinities at 5-HT transporter (K(i)=4.9nM), 5-HT(1A) receptor (K(i)=6.2nM) and functioned as a 5-HT(1A) receptor antagonist.
基于先前报道的先导发现物3-(顺式-4-(4-(1H-吲哚-4-基)哌嗪-1-基)环己基)-5-氟-1H-吲哚(2),合成了一系列相关的芳基哌嗪-4-基-环己基吲哚类似物,然后将其作为5-羟色胺转运体抑制剂和5-羟色胺(1A)受体拮抗剂进行评估。构效关系研究揭示了该系列活性所需的最佳药效基团元素。本研究中最佳的例子,5-(哌嗪-1-基)喹啉类似物(反式-20),在5-羟色胺转运体(Ki = 4.9 nM)、5-羟色胺(1A)受体(Ki = 6.2 nM)上表现出相同的结合亲和力,并作为5-羟色胺(1A)受体拮抗剂发挥作用。